

SENATE BILL 2240

By Haile

AN ACT to amend Tennessee Code Annotated, Title 33;
Title 53; Title 63 and Title 68, relative to the
prescribing of buprenorphine.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:

SECTION 1. The department of mental health and substance abuse services shall study the effect of rules promulgated pursuant to § 53-11-311(g) on the prescribing of buprenorphine products in nonresidential office-based opiate treatment facilities, nonresidential substitution-based treatment centers for opiate addiction, pharmacies, and hospitals in this state for calendar years 2019, 2020, and 2021. The study must include an examination of the effect of the rules on patient access, prescriber availability, and the delivery of substance abuse treatment in this state. The department shall report its findings and any recommendations for legislative action by the general assembly to the health and welfare committee of the senate and the health committee of the house of representatives no later than February 1, 2023.

SECTION 2. This act takes effect upon becoming a law, the public welfare requiring it.